MOL CLASS 23 - Enzymes and Drug Design (Part 2) (class notes S11)

MOL CLASS 23 - Enzymes and Drug Design (Part 2) (class notes S11)

Info iconThis preview shows pages 1–16. Sign up to view the full content.

View Full Document Right Arrow Icon
1 NATURAL SCIENCE II: MOLECULES OF LIFE Spring 2011 Class 23 – Wednesday, April 27 Enzymes and Drug Design – Part 2 Reading: Chapter 20, pp. 16 – 25 Next class: Benderly – Experimental Drugs on Trial OUTLINE (1) (2) HIV protease inhibitor drugs (3) The end of AIDS? (4) HIV mutations and drug resistance (5) (6) How are new drugs tested and approved?
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
ANNOUNCEMENTS
Background image of page 2
3 REVIEW E E I I
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
4 DESIGNING AN HIV PROTEASE INHIBITOR
Background image of page 4
5 CRIXIVAN: An HIV protease inhibitor
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
6 HIV PROTEASE INHIBITOR DRUGS Agenerase (amprenavir) Kaletra (lopinavir) Reyataz (atazanavir)
Background image of page 6
7 THE END OF AIDS? The power of the newest drugs, called protease inhibitors, and the even greater power of those in the pipeline, is such that a diagnosis of HIV infection is not just different in degree today than, say, five years ago. It is different in kind. It no longer signifies death. It merely signifies illness. Andrew Sullivan, 1996 0 10 20 30 40 50 60 1980
Background image of page 7

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 8
Background image of page 9

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 10
Background image of page 11

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 12
Background image of page 13

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 14
Background image of page 15

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Background image of page 16
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 1985 1990 1995 2000 Year AIDS deaths (thousands) 8 A MEDICAL MYSTERY 9 NOVA VIDEO 10 HIV MUTATIONS & DRUG RESISTANCE ASPIRIN & VIOXX REVISITED 11 C OO H arachidonic acid C OO H O O O O H a prostaglandin molecule CYCLO-OXYGENASE ENZYME HOW DOES ASPIRIN WORK? 12 SELECTIVE AND NON-SELECTIVE INHIBITORS 13 COX - 1 COX - 2 arachidonic acid protective prostaglandins inflammatory prostaglandins blood clot formation stomach mucus inflammation protective physiological function immune response on all the time switched on or off WHY IS VIOXX A SELECTIVE INHIBITOR? 14 C O O O C O CH 3 H O O S O O H 3 C aspirin vioxx 15 HOW ARE NEW DRUGS TESTED & APPROVED? Preclinical research Clinical trials 16 COSTS AND SUCCESS OF NEW DRUGS In 2003, the Center for the Study of Drug Development (Tufts University) calculated that an FDA approved drug costs $897 million (on average) to develop....
View Full Document

This note was uploaded on 11/07/2011 for the course MAP V55.0310.0 taught by Professor Tracejordan during the Spring '11 term at NYU.

Page1 / 16

MOL CLASS 23 - Enzymes and Drug Design (Part 2) (class notes S11)

This preview shows document pages 1 - 16. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online